News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
14-3-3η: Informing the RA Continuum of Care
14-3-3η Informs the RA Continuum of Care Vancouver, BC – October 28, 2016. At the world’s premier rheumatology conference, the American College of Rheumatology Annual Meeting (ACR) in Washington, DC, November 11-16, international investigators from Sweden, the United...
JOINTstat™ (14-3-3η); New Possibilities in RA
Augurex Life Sciences Corp. announces big leaps forward for applications of the JOINTstat™ (14-3-3η) blood test in rheumatoid arthritis (RA). Disease management is quickly moving upstream toward earlier identification and treatment, in some cases even pre-disease, and...
JOINTstat™ cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA)
Augurex is pleased to announce that the JOINTstat™ (14-3-3η) blood test has been cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA). The test is indicated for the diagnosis of rheumatoid arthritis (RA) and the assessment and monitoring...
Augurex Presenting at World Congress on Inflammation
At the 12th World Congress on Inflammation in Boston from August 8-12, Dr. Anthony Marotta will be co-chairing Symposium #29: Biomarkers in Inflammation: Focus on Rheumatoid Arthritis and will be delivering the following two presentations alongside presenter and...
JOINTstat™ – Expanding the Impact
Expanded Use Indications JOINTstat™, a clinically game-changing blood test for Rheumatoid Arthritis (RA), now has expanded use indications in Canada and the EU. This novel test, which measures a protein called 14-3-3η, was first indicated for diagnostic use in RA....
New Testing And Treatment Improves Outlook For Those With Rheumatoid Arthritis
PREVENTION AND TREATMENT If you have been experiencing a prolonged period of pain, tenderness and stiffness around your joints, you should get to a doctor — and make it fast. Please read the full article on the personalhealthnews.ca website here...
JOIN OUR WEBINAR: JOINTstat™ – A New Blood Test for Rheumatoid Arthritis Diagnosis
Canadian Rheumatologist Webinar You are invited to: Introducing JOINTstat™ (14-3-3η): A New Biomechanistic Marker for the Early Diagnosis and Prognosis of Rheumatoid Arthritis Presenter: Walter P. Maksymowych, MD F.R.C.P.(C) Professor and Medical Scientists in the...
JOINTstat™ – Transforming RA Patient Management
LifeLabs Medical Laboratory Services, the country's largest provider of community laboratory services, yesterday announced the Canadian launch of JOINTstat™ (14-3-3η), a biomarker blood test that is providing transformational insights into autoimmune joint damage...
LifeLabs Launches Arthritis Blood Test JOINTstat™ (14-3-3eta) in Canada
TORONTO, ONTARIO and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 2, 2015) - LifeLabs Medical Laboratory Services ("LifeLabs") announced today the launch of JOINTstat™, a diagnostic blood test for rheumatoid arthritis. The JOINTstat™ blood test is the first test...
NRC and Augurex collaborate to improve treatments for rheumatoid arthritis
The National Research Council of Canada (NRC) and Augurex Life Sciences Corp. are proud to announce a collaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine. By combining their research and development expertise, NRC...
Arthritis Blood Test: 14-3-3eta Ground-Breaking Data
Vancouver, BC – May 29, 2014. Augurex Life Sciences Corp. announces a ground-breaking body of new data that will publish during the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology taking place June 11-14 in Paris. Investigators will present...
Rheumatoid Arthritis Blood Test (14-3-3eta) Data to be Presented at the World’s Premier Arthritis Conference
Vancouver, BC – October 25, 2013 - Augurex Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting, taking...
Blood Marker Can Help Diagnose Rheumatoid Arthritis; New Data at the 2012 Annual Meeting of the American College of Rheumatology
International arthritis investigators this week at the 2012 Annual Meeting of the American College of Rheumatology held in Washington, DC presented data related to the 14-3-3η protein and its auto-antibodies, a promising set of new blood-based markers from Augurex,...
Augurex Announces Exclusive License Agreement with Quest Diagnostics for the Development of Arthritis Biomarker 14-3-3η as a Testing Service in the U.S.
Augurex Life Sciences Corp. today announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex's rheumatoid arthritis (RA) 14-3-3η...
Exciting Update From the World of BC Biotechnology
When early discoveries are made at universities, they usually require additional research and funding to uncover what the innovation's clinical usefulness will be to patients and physicians. For example, in 2006 researchers at the University of British Columbia (Dr....
Protein Measured by a Blood Test Marks Joint Erosions in Arthritis
At Europe's premier arthritis congress, the European League Against Rheumatism (EULAR) last week in Berlin, researchers presented findings that a protein measurable in blood named 14-3-3η, marks the presence of joint damage in two different forms of arthritis,...
Novel Blood Test Identifies Patients with Early Rheumatoid Arthritis; Findings Reported at the American College of Rheumatology (ACR)
Not unlike cancer, disease outcome can be dramatically improved if RA is caught and treated early. Augurex Life Sciences Corp. reported that in Chicago at the American College of Rheumatology (ACR) Annual Scientific Meeting, world-leading arthritis researchers from...
Augurex Reports Positive Data for RA Blood Test and Drug Target at the Annual European Congress of Rheumatology (EULAR)
Company's novel biomarker and drug target could represent the first personalized medicine in RA promise for future targeted therapy in a multi-factorial disease. Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact